Citadel Advisors’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-12,400
| Closed | -$199K | – | 15090 |
|
|
2021
Q2 | $199K | Sell |
12,400
-6,300
| -34% | -$108K | ﹤0.01% | 12174 |
|
|
2021
Q1 | $334K | Sell |
18,700
-57,300
| -75% | -$990K | ﹤0.01% | 10592 |
|
|
2020
Q4 | $1.03M | Buy |
76,000
+5,200
| +7% | +$62.8K | ﹤0.01% | 6744 |
|
|
2020
Q3 | $833K | Buy |
+70,800
| New | +$862K | ﹤0.01% | 6364 |
|
|
2020
Q2 | – | Sell |
-13,100
| Closed | -$177K | – | 10743 |
|
|
2020
Q1 | $177K | Sell |
13,100
-89,500
| -87% | -$1.7M | ﹤0.01% | 8136 |
|
|
2019
Q4 | $2.48M | Sell |
102,600
-67,500
| -40% | -$1.4M | ﹤0.01% | 4073 |
|
|
2019
Q3 | $3.27M | Buy |
170,100
+151,900
| +835% | +$3.48M | ﹤0.01% | 3721 |
|
|
2019
Q2 | $538K | Sell |
18,200
-5,100
| -22% | -$197K | ﹤0.01% | 6715 |
|
|
2019
Q1 | $1.11M | Sell |
23,300
-21,900
| -48% | -$964K | ﹤0.01% | 5405 |
|
|
2018
Q4 | $1.63M | Sell |
45,200
-9,900
| -18% | -$464K | ﹤0.01% | 4479 |
|
|
2018
Q3 | $3.39M | Buy |
55,100
+35,300
| +178% | +$2.27M | ﹤0.01% | 3540 |
|
|
2018
Q2 | $1.34M | Buy |
19,800
+10,200
| +106% | +$571K | ﹤0.01% | 4733 |
|
|
2018
Q1 | $521K | Sell |
9,600
-15,500
| -62% | -$867K | ﹤0.01% | 5817 |
|
|
2017
Q4 | $1.5M | Buy |
25,100
+6,200
| +33% | +$376K | ﹤0.01% | 4030 |
|
|
2017
Q3 | $919K | Hold |
18,900
| – | – | ﹤0.01% | 4438 |
|
|
2017
Q2 | $993K | Buy |
18,900
+7,600
| +67% | +$354K | ﹤0.01% | 4084 |
|
|
2017
Q1 | $512K | Sell |
11,300
-11,000
| -49% | -$491K | ﹤0.01% | 4976 |
|
|
2016
Q4 | $844K | Sell |
22,300
-26,300
| -54% | -$995K | ﹤0.01% | 4092 |
|
|
2016
Q3 | $1.83M | Buy |
48,600
+29,700
| +157% | +$655K | ﹤0.01% | 3074 |
|
|
2016
Q2 | $333K | Buy |
+18,900
| New | +$306K | ﹤0.01% | 5065 |
|
|
2016
Q1 | – | Sell |
-5,700
| Closed | -$139K | – | 8319 |
|
|
2015
Q4 | $139K | Sell |
5,700
-5,500
| -49% | -$128K | ﹤0.01% | 6308 |
|
|
2015
Q3 | $199K | Buy |
11,200
+5,900
| +111% | +$107K | ﹤0.01% | 6166 |
|
|
2015
Q2 | $94K | Buy |
+5,300
| New | +$97.2K | ﹤0.01% | 7139 |
|
Citadel Advisors's AERI Position: Q4 2022 in Review
Citadel Advisors sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 228,542 shares — an estimated $3.46M sold.
Citadel Advisors first reported a position in AERI in Q2 2015 and held it in 28 quarters. The position peaked at $85.6M in Q3 2018. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Citadel Advisors reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Citadel Advisors sold 228,542 Aerie Pharmaceuticals shares in Q4 2022, an estimated $3.46M.
- Citadel Advisors first reported a position in Aerie Pharmaceuticals in Q2 2015 and held it in 28 quarters.
- Citadel Advisors's Aerie Pharmaceuticals position peaked at $85.6M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.